Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Cellular and Molecular Biology

Pharmacodynamic measurements of telomerase inhibition by GRN163L, a potent telomerase inhibitor, in mouse and rat vibrissa follicles

Ekaterina Bassett, Mary Ann Genzer, Calvin Harley, Robert Tressler and Ning Go
Ekaterina Bassett
Geron Corporation, Menlo Park, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary Ann Genzer
Geron Corporation, Menlo Park, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Calvin Harley
Geron Corporation, Menlo Park, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Tressler
Geron Corporation, Menlo Park, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ning Go
Geron Corporation, Menlo Park, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2008
  • Article
  • Info & Metrics
Loading
AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA

Abstract

1824

Telomerase is required for cell immortality, a hallmark of cancer, and is expressed in essentially all cancer types, but not in most normal adult tissues. Therefore, inhibition of telomerase is a promising anti-cancer treatment strategy. GRN163L is a lipidated oligonucleotide with potent telomerase inhibitory activity, and is currently in Phase I/II clinical trials in solid tumors and hematological cancers. A challenge in monitoring target effects during clinical trials is that the target tissues, especially solid tumors, are not easily accessible for sampling. For telomerase inhibition in xenograft studies, measuring target inhibition in tumor samples is difficult in part due to tissue sample heterogeneity, and the presence of factors in tissue extracts that may interfere with the telomerase assay. Recently, we developed an assay for using human hair follicles as a surrogate tissue for monitoring telomerase inhibition in patients (see abstract “Detection of telomerase inhibition by GRN163L, a potent telomerase inhibitor, in human hair follicle," E. Bassett, M.A. Genzer, C. Harley, R. Tressler, and N. F. Go). Therefore, we chose to investigate the effect of GRN163L on telomerase activity in mouse and rat vibrissa follicles. We found that plucked rodent vibrissa follicles from rats, wild-type mice, and nude mice contained robust telomerase activity, readily detectable by an acrylamide gel-based TRAP assay. Our studies showed that GRN163L inhibited both xenograft tumor growth and telomerase activity in the vibrissa follicles of treated animals. Furthermore, telomerase inhibition in rat vibrissa follicles was dose-dependent, and the target inhibitory effect persisted for several days after a single dose treatment with GRN163L. With their easy accessibility, rodent vibrissa follicles, especially those from nude mice commonly used in xenograft tumor models, can be used as a convenient surrogate tissue to monitor telomerase inhibition in in vivo.

Footnotes

  • 99th AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA

  • American Association for Cancer Research
Previous
Back to top
Cancer Research: 68 (9 Supplement)
May 2008
Volume 68, Issue 9 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Pharmacodynamic measurements of telomerase inhibition by GRN163L, a potent telomerase inhibitor, in mouse and rat vibrissa follicles
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Pharmacodynamic measurements of telomerase inhibition by GRN163L, a potent telomerase inhibitor, in mouse and rat vibrissa follicles
Ekaterina Bassett, Mary Ann Genzer, Calvin Harley, Robert Tressler and Ning Go
Cancer Res May 1 2008 (68) (9 Supplement) 1824;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Pharmacodynamic measurements of telomerase inhibition by GRN163L, a potent telomerase inhibitor, in mouse and rat vibrissa follicles
Ekaterina Bassett, Mary Ann Genzer, Calvin Harley, Robert Tressler and Ning Go
Cancer Res May 1 2008 (68) (9 Supplement) 1824;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Cellular and Molecular Biology

  • Abstract SY29-01: Functions of wild type and mutant p53
  • Abstract SY34-02: The impact of O2 availability on human cancer
  • Abstract SY19-01: Cell to cell variability in the responses of tumor cells to death ligands
Show more 3

p53, Telomerase, and Senescence: Poster Presentations - Proffered Abstracts

  • Bypass of drug resistance in the EW36 Burkitts lymphoma cell line through genetic- and drug-mediated sensitization for engagement in a pro-apoptotic p53 pathway.
  • Senescence-induced alterations of laminin chain expression modulate progression of prostate cancer
  • The recruitment of the histone demethylase RBP2 by Mad1 for the transcriptional repression of the Myc target gene telomerase reverse transcriptase (hTERT)
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement